20 Oct, 2021
Mr. LIANG Qibin, the former President of CMAB Biopharma, will join Genor Biopharma as Chief Technology Officer. With Mr. LIANG Qibin joining the company, it will further strengthen the innovation ability of core technologies and achieve efficient innovation in technology, research and development, processes, management and other areas.
20 Sep, 2021
Dr. SHI Yuankai, M.D. Professor of Medical Oncology Department of Medical Oncology Deputy Director of National Cancer Center, Vice President of Cancer Hospital Chinese Academy of Medical Sciences & Peking Union Medical College, orally presented the clinical data at ESMO (European Society for Medical Oncology) Congress 2021. The clinical trial was designed to evaluate the efficacy and safety of Geptanolimab monotherapy in relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL).
10 Sep, 2021
Genor Biopharma (Stock code: 6998.HK) announced today that the latest clinical data on Geptanolimab (GB226) would be presented at ESMO (European Society for Medical Oncology) Congress 2021.
24 Mar, 2021
Significant progresses in IND, clinical development, NDA/BLA, commercialization, BD and financing
Submission of Application for First In Human Clinical Trial of GB261 to Bellberry Human Research Ethics Committee in Australia
17 Mar, 2021
SHANGHAI, China, March 17, 2021 -- Genor Biopharma (Stock code: 6998.HK) announced today that the Company has submitted a clinical trial application to the Bellberry Human Research Ethics Committee in Australia for First In Human (FIH) clinical trial of GB261, a novel CD20/CD3 bispecific antibody, in patients with B-cell non-Hodgkin Lymphoma (B-NHL).